FILE PHOTO: A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid
(Reuters) – AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
The treatment, ibrutinib, failed to show statistically significant improvement, compared to placebo, in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients.
Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Maju Samuel